BostonGene, NEC, and JIP Join Forces to Revolutionize Personalized Medicine in Japan

BostonGene, NEC Corporation, and Japan Industrial Partners (JIP) have announced the formation of BostonGene Japan Inc., a joint venture aimed at advancing personalized medicine and improving patient outcomes in Japan. This collaboration will leverage BostonGene's AI-based molecular and immune profiling solutions, NEC's expertise in IT, network, and AI technologies, and JIP's private equity support to accelerate the development and validation of novel precision medicine approaches.

With BostonGene's AI-powered cloud-based solutions, biocomputational algorithms, and advanced molecular and immune profiling, the new company will provide a comprehensive view of cancer patients at a molecular level. This will enable the identification of actionable targets and evidence-based treatment decisions. Additionally, BostonGene's platform offers a range of services for biopharma customers, including biomarker discovery, clinical trial testing, assay design and development, and companion diagnostics.

Cancer is a significant health concern in Japan, with one in four deaths attributed to the disease. The mortality rate is steadily rising, highlighting the urgent need for improved cancer care. By equipping cancer care centers in Japan with BostonGene's solutions, a greater number of patients will benefit from genomic testing and personalized treatments. Furthermore, Japanese researchers and biopharma companies will benefit from biomarker-driven therapy development through the utilization of BostonGene's industry solutions.

The collaboration between BostonGene, NEC Corporation, and JIP is expected to transform cancer care in Japan by enabling personalized treatments and improving therapy development. Andrew Feinberg, President and CEO of BostonGene, expressed excitement at bringing BostonGene's solutions to the Japanese market and the potential to significantly enhance the standard of cancer care in Japan.

NEC Corporation, known for its healthcare and life science business, aims to utilize powerful AI and digital technologies to support BostonGene's solutions and transform cancer care in Japan. With a strong customer base in its hospital DX business, NEC's collaboration with BostonGene will help Japanese pharmaceutical companies in developing the most effective therapies. Takayuki Morita, President and CEO of NEC Corporation, highlighted the potential of BostonGene's solutions in revolutionizing cancer care in Japan.

Japan Industrial Partners (JIP), a Tokyo-based private equity firm, expressed its support for NEC's efforts to create a healthcare and life science business through collaboration with BostonGene. By utilizing BostonGene's technology, JIP aims to contribute to the growth and improvement of the healthcare sector in Japan.

The formation of BostonGene Japan Inc. is a significant step towards advancing personalized medicine in Japan. By combining the expertise and resources of BostonGene, NEC Corporation, and Japan Industrial Partners, the joint venture will drive innovation in cancer care and improve patient outcomes. The comprehensive molecular and immune profiling solutions provided by BostonGene will enable healthcare professionals to make more informed treatment decisions, leading to personalized therapies and better patient outcomes.

In conclusion, the collaboration between BostonGene, NEC Corporation, and Japan Industrial Partners marks a major milestone in the advancement of personalized medicine in Japan. With a focus on revolutionizing cancer care, the joint venture aims to improve patient outcomes through the utilization of AI-based molecular and immune profiling solutions. By bringing BostonGene's advanced technology to Japan, the partners envision a future where personalized treatments and improved therapy development become the norm in cancer care.